Impact of ER Protein Homeostasis on Metabolism by Yalcin, Abdullah & Hotamisligil, Gökhan S.
 
Impact of ER Protein Homeostasis on Metabolism
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Yalcin, Abdullah, and Gökhan S. Hotamisligil. 2013. “Impact of




Accessed February 19, 2015 3:39:46 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12064406
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAImpact of ER Protein Homeostasis on Metabolism
Abdullah Yalcin and Gökhan S. Hotamisligil
P
roper regulation of protein homeostasis in a cell
is critical for the health of the organism. Proteins,
intracellular or secreted, need to be produced
and maintained at the right quantity, folded into
their three-dimensional conformation with necessary
posttranslational modiﬁcations, targeted to their correct
destinations to insure their optimal function, and degraded
efﬁciently and disposed when needed. The overall process
is tightly regulated at many levels to increase or decrease
the rate of the synthesis and breakdown of polypeptides.
In most cases, failure to properly regulate any one of these
control points leads to a dysfunction at the cellular and
organismic level resulting in disease.
The endoplasmic reticulum (ER) is a cellular organelle
consisting of a vast tubular network, where about one-third
of all proteins are synthesized. Proteins secreted to extra-
cellular environment, membrane proteins, and proteins that
reside inside the ER lumen are all synthesized and folded
into their native conformation in this organelle. Later, most
of the posttranslational modiﬁcations are completed in the
Golgi compartment. Similar to cytoplasmic protein synthe-
sis machinery, ER-mediated protein synthesis involves
a complex molecular apparatus to insure the quantity and
quality of synthesized proteins (1). ER-mediated protein
synthesis and folding represent unique challenges com-
pared with its cytoplasmic counterpart due to the high ox-
idative environment and high calcium concentrations of the
ER lumen (2). Problems arising at the synthesis and folding
stages lead to the appearance and accumulation of unfolded
proteins in the ER lumen that have to be efﬁciently cleared
using the primary protein degradation machine, the 26S
proteasome, which mediates degradation of most of the
ER resident as well as cytoplasmic proteins (3). Misfolded
proteins, as well as the organelle itself, can also be removed
through autophagy (4). Synthesis and degradation ma-
chinery interact with each other closely, and it is widely
accepted that dysfunction of either of these processes
compromises the efﬁciency of the other. If unfolded pro-
teins appear in the lumen, a cellular adaptation program
named the unfolded protein response (UPR) is triggered to
increase the folding and degradation capacity of the ER.
Once the burden of unfolded proteins is removed, UPR
response is silenced to its initial basal state. Prolonged or
inappropriate UPR responses are causally linked to various
pathologies including neurodegenerative diseases, obesity,
and diabetes (5,6).
Degradation and removal of unfolded proteins from the
ER system are speciﬁcally named as ER-associated deg-
radation (ERAD). Defects in ERAD are associated with an
increasing number of human diseases, including metabolic
diseases (7). One plausible mechanism linking ERAD
dysfunction to pathological states involves chronic UPR
responses resulting from the negative impact of a defective
ERAD on the protein synthesis and folding machinery.
Consistent with this hypothesis, a large number of ER
chaperones, which normally assist protein folding, were
shown to be involved in targeting unfolded proteins to
ERAD pathway, providing further support that the two
processes are simultaneously controlled (8,9).
New evidence of ERAD dysfunction leading to diabetes
emerged from a study by Otoda et al. (10), which is reported
in this issue of Diabetes. The initial leads that prompted
Otoda et al. to investigate the involvement of protein deg-
radation dysfunction in obesity and related metabolic dis-
eases came from expression proﬁling of obese and diabetic
human patients. As previously reported in obese liver tissue
in mouse models (11), the expression of several members
of proteasome-mediated degradation machinery was in-
creased. Interestingly, however, the authors detected a
signiﬁcant decrease in the activity of the proteasome ac-
companied by the accumulation of ubiquinated proteins in
liver tissue in various mouse models of diabetes. The
authors suggest that increased expression of components of
the proteasome system is a result of feedback cellular ad-
aptation to the decreased proteasome activity.
Otoda et al. next generated a genetic mouse model
lacking all three isoforms of the PA28A family of proteasome
activator genes to test whether compromised protein
degradation is causal to metabolic disease. Deletion of
PA28A genes did, in fact, resulted in signiﬁcantly de-
creased proteasome activity and accumulation of ubiqui-
nated proteins in liver tissue lysates. Importantly, this state
was accompanied by increased hepatic glucose production
even in the presence of high levels of insulin. Experiments,
in vivo, also provided support to the presence of hepatic
insulin resistance, despite the fact that liver tissue analysis
appeared normal except for a rather mild increase in lipid
accumulation. However, a more detailed examination of
hepatocytes by electronmicroscopy revealed unusual ex-
pansion and disorganization of ER membranes in cells
lacking PA28A subunits a, b, and g. This observation
prompted the investigators to hypothesize that ER stress
maybe the mechanistic link between proteasome dys-
function, insulin resistance, and abnormal glucose metab-
olism. This is a sound postulate as many independent studies
have ﬁrmly established that there is chronic ER stress in liver
tissue both in experimental models and in humans with
obesity and type 2 diabetes (12–14). Furthermore, proteasome
dysfunction induced by speciﬁc inhibition of hepatic
CYP3A has been shown to trigger UPR response in cul-
tured rat hepatocytes (15). Consistently, PA28A-deﬁcient ani-
mals displayed increased UPR response, evident by elevated
expression of several ER stress indicators such as PERK,
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mulation, JNK activation, and the consequential decrease in
insulin-induced Akt phosphorylation. These results de-
monstrate that experimentally induced defects in proteasome
activity can be sufﬁcient to cause ER stress and lead to insulin
resistance.
Several important questions are raised from these obser-
vations to explore and address in the future. It is interesting
that Otoda et al. observed further increase in the ubiqui-
nated proteins in PA28A-deﬁcient animals on a high-fat diet.
Since there are other proteasome complexes in the cell
such as the PA700-containing complexes (3), it is likely that
the remaining proteasome activity may also be susceptible
to dietary challenges and cues. Moreover, earlier studies
have shown defective autophagic responses in the liver of
obese mice (16). Autophagy is an important cellular process
by which proteins and cellular organelles are degraded in
lysosomes and contribute to protein and organelle turnover
in the cell. Besides, degradation obviously is not the only
control apparatus for protein homeostasis, therefore syn-
thetic pathways might also play a role in this condition.
Increased lipid accumulation in hepatocytes might be a
consequence of hepatic insulin resistance and ER stress
activation. Interestingly, lipoprotein synthesis is regulated
by ERAD via degradation of ER resident lipogenic enzyme
HMG-CoA (17). It is possible that other ER enzymes of de
novo lipogenesis pathway are also ERAD substrates.
Otoda et al. postulate that increased hepatic glucose
production may be linked to increased nuclear Foxo1 ac-
tivity due to inefﬁcient degradation of phosphorylated
Foxo1 protein by the proteasome. In this scenario, one
would expect accumulation of the phosphorylated form of
Foxo1 in the cytoplasmic compartment. Surprisingly,
phosphorylated Foxo1 is lower in PA28A-deﬁcient animals
compared with wild-type controls suggesting that protea-
somal dysfunction might not be the main reason for de-
creased Foxo1 degradation. Akt phosphorylates Foxo1
upon insulin stimulation, preventing its nuclear transport
(18); therefore decreased Akt activity might contribute to
inefﬁcient exclusion of Foxo1 from the nucleus and tar-
geting to proteasomal degradation.
And ﬁnally, it is not clear if the accumulation of a sub-
strate of UPS in ER lumen, cytoplasm, or even in the nu-
cleus, triggers downstream signaling events. For instance,
ubiquinated Huntington protein aggregates and forms cy-
toplasmic and intranuclear inclusion bodies, which corre-
late with the progression of Huntington disease. While the
contribution of these inclusion bodies to neuronal cell death
and disease pathogenesis remains a subject of debate (19),
it is quite possible that intermediary misfolded products and
their accumulation at levels insufﬁcient to form aggregates,
can directly engage ER stress responses. At the moment,
there is no clear evidence to support this possibility.
In summary, the results of this study illustrate that obe-
sity correlates with impaired UPS and reduced proteasomal
degradation in hepatocytes, thus leading to activation of
chronic UPR responses, hepatic insulin resistance, and in-
creased hepatic glucose production. This model is also
supported by the ﬁndings that treating PA28A-deﬁcient ani-
mals with a chemical chaperone phenylbutyric acid (PBA)
ameliorated ER stress and increased hepatic insulin re-
sponse. It is yet unclear whether the ﬁnding reported by
Otoda et al. indicate defects in overall protein turnover rates
or those of speciﬁc proteins. This question is of interest
since systems approaches have demonstrated diminished
protein synthesis in obesity in the obese liver tissue (11).
Hence the net result of these changes on protein homeo-
stasis is not known at this point and would be interesting to
explore.
Most striking ﬁnding of Otoda et al. is decreased pro-
teasomal function by metabolic interventions such as in-
creased caloric intake and increased fat content in the
diet. What initiates these disturbances in the ER protein
synthesis and degradation systems remains a critical fu-
ture area of research. Increased hepatic lipogenesis (11),
circulating fatty acids and other nutrients (20), and expo-
sure to oxidative stress arising from increased oxidative
phosphorylation (21) and insulin (22) are some potential
candidates that may tip the balance of protein synthesis
and degradation systems of the ER.
It is likely that there are close communication systems
linking ER protein homeostasis with UPS and autophagy
machinery through ERAD and ER turnover processes, re-
spectively. Any disturbance to this delicate balance results
in the induction of ER stress, metaﬂammation, insulin re-
sistance, and steatosis in liver tissue (Fig. 1). Which one of
these biological processes receives the ﬁrst signal from the
increased nutrient surplus during obesity remains to be
identiﬁed. The study by Otoda et al. uncovers an important
piece of the puzzle, adds to the model that obesity is ac-
companied by inherent abnormalities in homeostatic mech-
anisms that regulate protein turnover, and raises important
open questions for future studies.
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